三星生物推出药物筛选服务，三星类器官-动脉网

Samsung Biologics launches drug screening services, Samsung Organoids

CISION 等信源发布 2025-06-16 07:30



可切换为仅中文







Samsung Organoids

三星类器官

to provide data-driven analysis of candidate molecules

提供基于数据的候选分子分析

Samsung Biologics expands service scope to include preclinical research

三星生物制品公司扩大服务范围，涵盖临床前研究

INCHEON,

仁川，

South Korea

韩国

，

June 15, 2025

2025年6月15日

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of

/PRNewswire/ -- 三星生物制品公司（KRX: 207940.KS），一家领先的合同开发和制造组织（CDMO），今天宣布推出

Samsung Organoids

三星类器官

– advanced drug screening services to support clients in drug discovery and development.

- 先进的药物筛选服务，支持客户进行药物发现和开发。

Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. Organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction..

类器官是经过工程设计的三维细胞培养系统，能够高度模拟人体器官，为更好地理解特定药物反应和改进先导化合物筛选提供了临床相关见解。由于其与活体组织的高度相似性以及在生物标志物发现和药物疗效预测中的潜在应用，类器官正成为一种新的研究模型。

Samsung Organoids

三星类器官

support

支持

precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug (IND) filings through data-driven analysis of candidate molecules.

通过数据驱动的候选分子分析，进行精确筛选以预测患者反应、简化临床前开发，并加速推进至研究性新药（IND）申请的时间表。

With the launch, Samsung Biologics expands its business to include preclinical research, with service offerings spanning target discovery, lead selection, preclinical development, and clinical trial planning. Leveraging its expertise in development and manufacturing, the company will provide data-driven, multi-modal insights into the characteristics and mechanisms .

随着此次推出，三星生物制品公司将其业务扩展到包括临床前研究，服务范围涵盖靶点发现、先导物选择、临床前开发和临床试验规划。凭借其在开发和制造方面的专业知识，该公司将提供基于数据的、多模式的特性和机制洞察。

of candidate

候选人

molecules. By helping clients address challenges that may arise during the drug discovery phase, Samsung Biologics aims to enhance clinical success rates.

分子。通过帮助客户解决在药物发现阶段可能出现的挑战，三星生物制品公司旨在提高临床成功率。

'The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,' said

“最新的服务推出反映了我们通过提高药物成功率和在个性化医疗领域创造新可能性来推动创新的坚定承诺，”

John Rim

约翰·林

, CEO and President of Samsung Biologics. 'The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.'

三星生物制品公司首席执行官兼总裁表示：“增加研发服务是我们为客户提供附加价值的重要举措，通过深入的治疗分析来支持药物生命周期的各个环节。”

About Samsung Biologics

三星生物制品公司简介

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

三星生物制品（KRX: 207940.KS）是一家领先的合同开发和制造组织（CDMO），提供从后期发现到商业生产的端到端综合服务。

With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

三星生物制药公司在五个工厂拥有总计784千升的生物制造产能，利用尖端技术和专业知识推进多种模式的发展，包括多特异性抗体、融合蛋白、抗体药物偶联物和mRNA疗法。

Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and

三星生物制品公司经营着一个全球网络，在韩国、美国和其他地区拥有设施和办公室，

Japan

日本

. Samsung Biologics America supports clients based in the U.S. and

三星生物美国公司为美国本土的客户提供支持，并且

Europe

欧洲

, while its

，而其

Tokyo

东京

sales office serves the APAC region.

销售办公室服务于亚太地区。

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health..

三星生物制品公司继续投资于新的能力，以最大化运营和质量的卓越性，确保客户的灵活性和敏捷性。该公司致力于准时、全额交付安全、高质量的产品，并作出有利于社会和全球健康的可持续商业决策。

For more information, please visit

欲了解更多信息，请访问

https://samsungbiologics.com/

Samsung Biologics Media Contact

三星生物媒体联络部

Claire Kim

金克莱尔

cair.kim@samsung.com

SOURCE Samsung Biologics

来源：三星生物制品公司

WANT YOUR COMPANY'S NEWS